View New Articles By
Damon Runyon is delighted to announce that the 2021 Nobel Prize in Physiology or Medicine has been awarded jointly to David Julius, PhD, and Ardem Patapoutian, PhD, "for their discoveries of receptors for temperature and touch."
For Vassiliki Karantza, MD, PhD, the past seven years have been a whirlwind. Since starting her first job in the pharmaceutical industry in 2014, the former Damon Runyon Clinical Investigator has overseen the development of a new drug for breast cancer from early clinical trials to approval by the Food and Drug Administration. As of March 2021, the drug, pembrolizumab (Keytruda), is FDA-approved for the treatment of metastatic triple-negative breast cancer (TNBC), which accounts for 10-15% of breast cancer diagnoses. It is a remarkable achievement, especially considering that the company’s breast cancer program did not yet exist when Dr. Karantza arrived.
Grants totaling nearly $4 million give early-career investigators independence to pursue brave and bold cancer research.
Damon Runyon is pleased to announce that Meghan Raveis was elected to the Board of Directors in June.
Damon Runyon Cancer Research Foundation has announced the 2021 recipients of the Damon Runyon Clinical Investigator award—six outstanding early career physician-scientists working to develop new cancer therapies under the mentorship of the nation's leading scientists and clinicians.
Note: This is an extended version of an interview published in the Spring 2021 issue of our print newsletter, Momentum.
Former Damon Runyon Clinical Investigator Li Li, MD, PhD, MPH has been appointed to the U.S. Preventive Services Task Force, a sixteen-member panel of experts that makes recommendations for screenings and other preventive healthcare measures for the entire U.S. population. He spoke with us about the role of prevention in the continuum of cancer care.
ArvCon, now in its seventh year, is a weekend featuring multiple tabletop roleplaying game sessions, a concert, giveaways, and other surprises, benefiting the Damon Runyon Cancer Research Foundation. Damon Runyon’s award programs are targeted to have the greatest impact on cancer research, providing critical early career support to researchers pursuing work with a high potential to impact all types of cancer. Damon Runyon’s mission is to foster new generations of elite scientists and fill gaps in traditional research funding that threaten future breakthroughs.
Five scientists with exceptional promise and novel approaches to fighting cancer have been named the 2021 recipients of the Damon Runyon Physician-Scientist Training Award. The awardees were selected through a highly competitive and rigorous process by a scientific committee comprised of leading cancer researchers who are themselves physician-scientists.
In addition to his Damon Runyon-funded research project, which aims to optimize the delivery of the chemotherapy drug cisplatin, Quantitative Biology Fellow Vitor Mori, PhD, has dedicated some of his efforts over the past year to addressing the COVID-19 crisis in his home city of Sao Paulo, Brazil. The most populous city in the Western and Southern hemispheres, Sao Paolo has been struck particularly hard by the pandemic – Brazil’s COVID-19 death toll is second only to the United States.
The second class of Damon Runyon Quantitative Biology Fellows, announced this month, will apply the tools of computational biology to generate and interpret cancer research data at extraordinary scale and resolution. From RNA sequencing data that pinpoints tumor cells to their exact location to three-dimensional models of cell-cell interaction, their projects extend the boundaries of what is possible in cancer research, allowing them to tackle fundamental biological and clinical questions.
CONNECT
1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006
